Australia
· Delayed Price · Currency is AUD OncoSil Medical Statistics
Total Valuation
OncoSil Medical has a market cap or net worth of AUD 18.43 million. The enterprise value is 10.03 million.
| Market Cap | 18.43M |
| Enterprise Value | 10.03M |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoSil Medical has 4.61 billion shares outstanding. The number of shares has increased by 98.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.61B |
| Shares Change (YoY) | +98.54% |
| Shares Change (QoQ) | +61.39% |
| Owned by Insiders (%) | 11.20% |
| Owned by Institutions (%) | 11.68% |
| Float | 3.80B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.65 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.80 |
| EV / Sales | 5.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.81 |
| Quick Ratio | 3.61 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -199.38% and return on invested capital (ROIC) is -122.79%.
| Return on Equity (ROE) | -199.38% |
| Return on Assets (ROA) | -87.77% |
| Return on Invested Capital (ROIC) | -122.79% |
| Return on Capital Employed (ROCE) | -146.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.09 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 44.98 |
| Average Volume (20 Days) | 2,995,491 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoSil Medical had revenue of AUD 1.91 million and -12.60 million in losses. Loss per share was -0.00.
| Revenue | 1.91M |
| Gross Profit | 256,555 |
| Operating Income | -12.59M |
| Pretax Income | -12.60M |
| Net Income | -12.60M |
| EBITDA | -12.59M |
| EBIT | -12.59M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 8.47 million in cash and 70,843 in debt, giving a net cash position of 8.40 million or 0.00 per share.
| Cash & Cash Equivalents | 8.47M |
| Total Debt | 70,843 |
| Net Cash | 8.40M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 8.56M |
| Book Value Per Share | 0.00 |
| Working Capital | 8.17M |
Cash Flow
In the last 12 months, operating cash flow was -12.63 million and capital expenditures -208,405, giving a free cash flow of -12.84 million.
| Operating Cash Flow | -12.63M |
| Capital Expenditures | -208,405 |
| Free Cash Flow | -12.84M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 13.43% |
| Operating Margin | -659.37% |
| Pretax Margin | -659.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoSil Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -98.54% |
| Shareholder Yield | -98.54% |
| Earnings Yield | -68.40% |
| FCF Yield | -69.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoSil Medical has an Altman Z-Score of -9.13. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.13 |
| Piotroski F-Score | n/a |